The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy

This publication has 8 references indexed in Scilit:

• The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
  European Journal Of Cancer, 1993
• Decision Analysis of Hematopoietic Growth Factor Use in Patients Receiving Cancer Chemotherapy
  JNCI Journal of the National Cancer Institute, 1993
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
  European Journal Of Cancer, 1993
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
  New England Journal of Medicine, 1991
• The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
  British Journal of Cancer, 1989
• Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
  New England Journal of Medicine, 1988
• EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY
  The Lancet, 1988
• Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia
  Annals of Internal Medicine, 1966